Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 09 04:00PM ET
15.29
Dollar change
+0.48
Percentage change
3.24
%
Index- P/E- EPS (ttm)-0.96 Insider Own89.09% Shs Outstand350.91M Perf Week10.32%
Market Cap5.37B Forward P/E17.49 EPS next Y0.87 Insider Trans0.00% Shs Float38.31M Perf Month-2.24%
Income-337.00M PEG- EPS next Q0.14 Inst Own11.17% Short Float4.25% Perf Quarter10.16%
Sales4.31B P/S1.24 EPS this Y-12.45% Inst Trans20.84% Short Ratio3.07 Perf Half Y-8.17%
Book/sh18.95 P/B0.81 EPS next Y36.80% ROA-2.76% Short Interest1.63M Perf Year-16.90%
Cash/sh0.93 P/C16.51 EPS next 5Y15.30% ROE-4.94% 52W Range13.16 - 21.95 Perf YTD-10.38%
Dividend Est.- P/FCF- EPS past 5Y- ROI-3.01% 52W High-30.34% Beta0.47
Dividend TTM- Quick Ratio1.03 Sales past 5Y2.77% Gross Margin54.78% 52W Low16.19% ATR (14)0.62
Dividend Ex-Date- Current Ratio1.70 EPS Y/Y TTM-223.22% Oper. Margin4.91% RSI (14)54.47 Volatility4.58% 4.50%
Employees13300 Debt/Eq0.69 Sales Y/Y TTM13.23% Profit Margin-7.81% Recom1.93 Target Price18.25
Option/ShortYes / Yes LT Debt/Eq0.68 EPS Q/Q-85.03% Payout- Rel Volume1.37 Prev Close14.81
Sales Surprise2.92% EPS Surprise-0.43% Sales Q/Q18.05% EarningsMay 01 BMO Avg Volume529.93K Price15.29
SMA205.51% SMA50-2.08% SMA200-6.13% Trades Volume724,327 Change3.24%
Date Action Analyst Rating Change Price Target Change
May-06-24Upgrade Morgan Stanley Equal-Weight → Overweight $16 → $18
Jan-04-24Downgrade Evercore ISI Outperform → In-line $19 → $17
Dec-12-23Initiated Stifel Hold $16
Oct-03-23Resumed Evercore ISI Outperform $20
May-30-23Resumed Morgan Stanley Equal-Weight $20
Mar-09-23Initiated Needham Hold
Dec-21-22Initiated Barclays Equal Weight $17
Sep-12-22Initiated H.C. Wainwright Buy $21
Jul-26-22Initiated RBC Capital Mkts Outperform $22
Jun-24-22Initiated Evercore ISI Outperform $21
May-03-24 04:06PM
03:35PM
May-02-24 03:03PM
May-01-24 11:54AM
08:33AM
06:58AM Loading…
06:58AM
Apr-29-24 07:00AM
Apr-25-24 08:30AM
Apr-24-24 10:01AM
Apr-18-24 07:00AM
Apr-15-24 12:00PM
Mar-27-24 07:00AM
Mar-25-24 12:00PM
Mar-20-24 12:20PM
Mar-19-24 08:50AM
10:10AM Loading…
Mar-08-24 10:10AM
Feb-28-24 08:00AM
Feb-23-24 03:05PM
Feb-22-24 11:30AM
Feb-21-24 10:35PM
07:04PM
09:30AM
07:36AM
07:31AM
07:00AM
06:58AM
Feb-15-24 09:15AM
Feb-14-24 12:10PM
10:00AM
Feb-05-24 12:00PM
06:54PM Loading…
Jan-17-24 06:54PM
Jan-09-24 12:41PM
Jan-08-24 06:59AM
Jan-03-24 09:00AM
Nov-28-23 01:25PM
Nov-15-23 06:59AM
Nov-03-23 11:01AM
Nov-01-23 03:19PM
09:21AM
06:58AM
Oct-26-23 06:59AM
Oct-16-23 12:00PM
Oct-04-23 06:59AM
Sep-29-23 10:15AM
10:00AM
Sep-26-23 06:59AM
Sep-20-23 06:59AM
Sep-19-23 08:32AM
Sep-18-23 11:56AM
Sep-14-23 05:25PM
Sep-12-23 06:59AM
Sep-11-23 08:00AM
07:07AM
Sep-06-23 05:58PM
06:59AM
Aug-29-23 07:00AM
Aug-24-23 07:00AM
Aug-02-23 05:25PM
06:59AM
Aug-01-23 08:00AM
Jul-11-23 07:00AM
Jul-06-23 07:00AM
Jul-03-23 10:12AM
Jun-30-23 06:48PM
08:30AM
08:28AM
08:00AM
Jun-14-23 09:43AM
Jun-12-23 07:00AM
Jun-08-23 07:00AM
Jun-06-23 07:00AM
Jun-05-23 07:00AM
Jun-01-23 07:00AM
May-18-23 01:56PM
08:50AM
May-08-23 06:53PM
May-03-23 06:59AM
May-01-23 07:00AM
Apr-26-23 07:00AM
Apr-25-23 07:00AM
Apr-24-23 07:00AM
Apr-20-23 07:00AM
Apr-18-23 11:02AM
07:00AM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 07:00AM
Mar-31-23 10:15PM
Mar-29-23 04:39PM
Mar-22-23 07:00AM
Mar-08-23 07:02PM
Feb-23-23 10:47PM
05:28AM
Feb-22-23 06:59AM
Feb-15-23 07:02PM
07:30AM
06:58AM
Feb-07-23 07:00AM
Feb-01-23 07:00AM
Jan-23-23 07:00AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Last Close
May 09 04:00PM ET
6.95
Dollar change
-0.08
Percentage change
-1.14
%
Index- P/E- EPS (ttm)-1.24 Insider Own2.41% Shs Outstand365.24M Perf Week-14.09%
Market Cap2.55B Forward P/E1.65 EPS next Y4.21 Insider Trans-0.07% Shs Float357.94M Perf Month-22.09%
Income-455.00M PEG- EPS next Q0.88 Inst Own78.79% Short Float5.79% Perf Quarter-14.51%
Sales8.97B P/S0.28 EPS this Y4.59% Inst Trans18.35% Short Ratio6.63 Perf Half Y-4.14%
Book/sh-3.04 P/B- EPS next Y16.09% ROA-1.74% Short Interest20.71M Perf Year18.60%
Cash/sh2.06 P/C3.38 EPS next 5Y2.60% ROE- 52W Range5.57 - 11.46 Perf YTD-13.34%
Dividend Est.- P/FCF3.22 EPS past 5Y32.76% ROI-2.23% 52W High-39.35% Beta0.86
Dividend TTM- Quick Ratio0.85 Sales past 5Y1.03% Gross Margin58.79% 52W Low24.77% ATR (14)0.40
Dividend Ex-DateAug 30, 2010 Current Ratio1.22 EPS Y/Y TTM-26.24% Oper. Margin18.66% RSI (14)20.97 Volatility5.55% 4.91%
Employees20270 Debt/Eq- Sales Y/Y TTM10.01% Profit Margin-5.07% Recom2.86 Target Price9.83
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q68.46% Payout- Rel Volume1.69 Prev Close7.03
Sales Surprise-0.27% EPS Surprise-7.39% Sales Q/Q10.75% EarningsMay 02 BMO Avg Volume3.12M Price6.95
SMA20-17.35% SMA50-23.86% SMA200-15.83% Trades Volume5,282,961 Change-1.14%
Date Action Analyst Rating Change Price Target Change
Sep-20-23Upgrade Jefferies Hold → Buy $9 → $16
Jun-16-23Downgrade TD Cowen Outperform → Market Perform
Jul-29-22Downgrade Truist Buy → Hold
Jul-29-22Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $5
Jul-28-22Downgrade JP Morgan Overweight → Neutral
Jun-13-22Resumed JP Morgan Overweight $12
Mar-24-21Downgrade BofA Securities Neutral → Underperform $27
Feb-17-21Upgrade RBC Capital Mkts Sector Perform → Outperform $26 → $42
Jan-22-21Downgrade Piper Sandler Overweight → Neutral $25 → $30
Sep-17-20Upgrade BofA Securities Underperform → Neutral $19
Today 08:00AM
May-06-24 03:02PM
06:52AM
May-03-24 04:06PM
03:35PM
12:42PM Loading…
12:42PM
09:34AM
May-02-24 06:43PM
01:54PM
12:29PM
11:38AM
11:04AM
10:57AM
08:38AM
08:35AM
07:54AM Loading…
07:54AM
07:32AM
07:00AM
May-01-24 02:30PM
09:32AM
07:55AM
07:19AM
Apr-29-24 12:00PM
Apr-25-24 02:27PM
09:02AM
Apr-23-24 12:04PM
Apr-22-24 12:41PM
Apr-20-24 09:16AM
Apr-11-24 04:22PM
01:03PM
12:40PM Loading…
12:40PM
12:10PM
11:17AM
11:03AM
08:00AM
Apr-08-24 05:33PM
01:27PM
Apr-05-24 06:15PM
Apr-03-24 12:05PM
09:50AM
08:00AM
Apr-02-24 08:00AM
Mar-28-24 02:19PM
05:23AM
Mar-15-24 09:50AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Mar-01-24 08:00AM
Feb-27-24 03:27AM
Feb-23-24 12:25PM
11:53AM
Feb-22-24 11:30AM
10:03AM
09:30AM
08:25AM
07:33AM
07:33AM
07:00AM
Feb-21-24 12:10PM
07:26AM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-12-24 08:00AM
Feb-08-24 10:59AM
Feb-07-24 12:00PM
Feb-01-24 04:10PM
08:00AM
Jan-31-24 04:00PM
Jan-30-24 05:54PM
08:00AM
Jan-18-24 04:50PM
08:00AM
Jan-08-24 11:15AM
Dec-22-23 10:23AM
Dec-21-23 07:00AM
Dec-18-23 09:40AM
08:00AM
Dec-13-23 07:43AM
Dec-11-23 09:55AM
Dec-05-23 08:00AM
Nov-30-23 09:40AM
Nov-24-23 09:55AM
Nov-13-23 09:55AM
Nov-10-23 12:42PM
08:00AM
Nov-08-23 08:00AM
Nov-03-23 02:03PM
12:47PM
Nov-02-23 04:13PM
11:00AM
09:41AM
08:34AM
07:00AM
Nov-01-23 12:22PM
10:43AM
10:40AM
09:30AM
07:07AM
Oct-31-23 02:58AM
Oct-30-23 04:35PM
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson SeanaEVP, General CounselMar 04 '24Sale9.806,31361,867499,905Mar 04 04:16 PM
Carson SeanaEVP, General CounselDec 05 '23Sale7.382201,624382,925Dec 05 04:35 PM
Carson SeanaEVP, General CounselNov 06 '23Sale7.6143327384,836Nov 06 05:06 PM
Carson SeanaEVP, General CounselSep 06 '23Sale8.286,68555,352385,213Sep 06 04:33 PM